Nicotinamide adenine dinucleotide analogues

A compound of Formula (I-B):

• or a tautomer thereof, or an N-oxide of each thereof, or a pharmaceutically acceptable salt of each of the aforementioned, or a pharmaceutically acceptable solvate of each of the foregoing, wherein:
• each of R5, R6, R7, R8, R9, R10, and R11 independently is a hydrogen, —N3, a hydroxyl, an optionally substituted C1-C10 alkyl, an optionally substituted C2-C10 alkynyl, an optionally substituted C1-C10 alkoxy, —SR30, an optionally substituted C6-C10 aryl, an optionally substituted 5-15 membered heteroaryl, or Z;
• X5 is —S—, —O—, or —NR20-;
• each R20 and R30 is independently a hydrogen or an optionally substituted C1-C10 alkyl;
• Z is
• each n is independently 1-4 or 1, 3, or 4;
• each Y15 is independently a hydrogen, —NO2, a halo, a cyano, a hydroxyl, an optionally substituted C1-C6 alkyl, or an optionally substituted C1-C6 alkoxy;
• each Y25 is independently a hydrogen or an optionally substituted C1-C6 alkyl, and
• each Y20 is independently selected from the group consisting of:
• P is a cationic polypeptide of about 5 to 30 amino acid residues in length;
• L5 is a hydrogen, an optionally substituted C1-C6 alkyl, or -L1Y35;
• L1 is —PO2—, —PO3—PO2—, —PO3—PO3—PO2—, —P(═O)(R100)—, —P(═O)(R100)OP(═O)(R100)—, or —P(═O)(R100)OP(═O)(R100)OP(═O)(R100)—;
• each R100 is independently —O⊖, an optionally substituted C1-C10 alkyl group, or an optionally substituted C1-C10 alkoxy;
• and
• Y35 is a hydroxyl or an optionally substituted C1-C6 alkoxy.

A compound of Formula (I-C):

• or a tautomer thereof, or an N-oxide of each thereof, or a pharmaceutically acceptable salt of each of the aforementioned, or a pharmaceutically acceptable solvate of each of the foregoing, wherein
• each R1, R2, R3, and R4 independently is a hydrogen or an optionally substituted C1-C6 alkyl or Z;
• X is —S—, —O—, or —NR20—;
• R20 is a hydrogen or an optionally substituted C1-C10 alkyl;
• Z is
• each n is independently 1-4 or 1, 3, or 4;
• each Y15 is independently a hydrogen, —NO2, a halo, a cyano, a hydroxyl, an optionally substituted C1-C6 alkyl, or an optionally substituted C1-C6 alkoxy;
• each Y25 is independently a hydrogen or an optionally substituted C1-C6 alkyl, and
• each Y20 is independently selected from the group consisting of:
• P is a cationic polypeptide of about 5-30 amino acid residues in length;
• Y30 is a hydrogen, an optionally substituted C1-C6 alkyl, an optionally substituted C2-C10 alkenyl, an optionally substituted C2-C10 alkynyl, an optionally substituted C6-C10 aryl, an optionally substituted 5-15 membered heteroaryl, or -L1Y35;
• L1 is —PO2—, —PO3—PO2—, —PO3—PO3—PO2—, —P(═O)(R100)—, —P(═O)(R100)OP(═O)(R100)—, or —P(═O)(R100)OP(═O)(R100)OP(═O)(R100)—;
• each R100 is independently —O⊖, an optionally substituted C1-C10 alkyl group, or an optionally substituted C1-C10 alkoxy;
• and
• Y35 is a hydroxyl or an optionally substituted C1-C6 alkoxy.

A compound of Formula (I-D):

• or a tautomer thereof, or an N-oxide of each thereof, or a pharmaceutically acceptable salt of each of the aforementioned, or a pharmaceutically acceptable solvate of each of the foregoing, wherein
• each of R1, R2, R3, and R4 independently is a hydrogen or an optionally substituted C1-C6 alkyl or Z;
• X is —S—, —O—, or —NR20—;
• R20 is a hydrogen or an optionally substituted C1-C10 alkyl;
• L10 is a hydrogen, an optionally substituted C1-C6 alkyl, or -L1Y35;
• L1 is —PO2—, —PO3—PO2—, —PO3—PO3—PO2—, —P(═O)(R100)—, —P(═O)(R100)OP(═O)(R100)—, or —P(═O)(R100)OP(═O)(R100)OP(═O)(R100)—;
• each R100 is independently —O⊖, an optionally substituted C1-C10 alkyl group, or an optionally substituted C1-C10 alkoxy;
• Y35 is a hydroxyl or an optionally substituted C1-C6 alkoxy;
• Z is
• each n is independently 1-4 or 1, 3, or 4;
• each Y15 is independently a hydrogen, —NO2, a halo, a cyano, a hydroxyl, an optionally substituted C1-C6 alkyl, or an optionally substituted C1-C6 alkoxy;
• each Y25 is independently a hydrogen or an optionally substituted C1-C6 alkyl, and
• each Y20 is independently selected from the group consisting of:
• and
• P is a cationic polypeptide of about 9-30 amino acid residues in length.

A compound of Formula (I):

• or a tautomer thereof, or an N-oxide of each thereof, or a pharmaceutically acceptable salt of each of the aforementioned, or a pharmaceutically acceptable solvate of each of the foregoing, wherein
• each R1, R2, R3, and R4 independently is a hydrogen or an optionally substituted C1-C6 alkyl or Z;
• X is —S—, —O—, or —NR20—;
• X5 is —S—, —O—, or —NR20-;
• L1 is —PO2—, —PO3—PO2—, —PO3—PO3—PO2—, —P(═O)(R100)—, —P(═O)(R100)OP(═O)(R100)—, or —P(═O)(R100)OP(═O)(R100)OP(═O)(R100)—;
• R100 is —O⊖, an optionally substituted C1-C10 alkyl group, or an optionally substituted C1-C10 alkoxy;
• each R5, R6, R7, R8, R9, R10, and R11 independently is a hydrogen, —N3, a hydroxyl, an optionally substituted C1-C10 alkyl, an optionally substituted C2-C10 alkynyl, an optionally substituted C1-C10 alkoxy, —SR30, an optionally substituted C6-C10 aryl, an optionally substituted 5-15 membered heteroaryl, or Z;
• Z is
• each n is independently 1-4 or 1, 3, or 4;
• each Y15 is independently a hydrogen, —NO2, a halo, a cyano, a hydroxyl, an optionally substituted C1-C6 alkyl, or an optionally substituted C1-C6 alkoxy;
• each Y25 is independently a hydrogen or an optionally substituted C1-C6 alkyl, and
• each Y20 is independently selected from the group consisting of:
• P is a cationic polypeptide of about 9-30 amino acid residues in length;
• and
• each R20 and R30 is independently a hydrogen or an optionally substituted C1-C10 alkyl.